NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge

scientific article published in September 2005

NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4049/JIMMUNOL.175.5.3092
P932PMC publication ID1360163
P698PubMed publication ID16116198
P5875ResearchGate publication ID7644956

P50authorMark J. SmythQ38544864
Andreas StrasserQ38803763
Philippe BouilletQ39186694
Andrew M LewQ56486071
Dale I GodfreyQ56957983
Yifan ZhanQ61283866
P2093author name stringAdam P Uldrich
Daniel G Pellicci
Konstantinos Kyparissoudis
Nadine Y Crowe
P2860cites workMouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b)Q24646967
Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunityQ28138855
CD1: antigen presentation and T cell functionQ28251508
TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cellsQ28589574
Analysis of Qa-1(b) peptide binding specificity and the capacity of CD94/NKG2A to discriminate between Qa-1-peptide complexesQ30918649
Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein BimQ33715752
Glycolipid presentation to natural killer T cells differs in an organ-dependent fashionQ33762686
Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cellsQ33818603
Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivoQ35168204
Alpha-galactosylceramide: potential immunomodulatory activity and future applicationQ35644413
IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2.Q35847866
Going both ways: immune regulation via CD1d-dependent NKT cellsQ35951531
The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansionQ35978664
Toward an understanding of NKT cell biology: progress and paradoxesQ36072480
Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramersQ36368804
CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetesQ36369438
Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma productionQ36369610
Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.Q36369797
Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered proteinQ36371349
The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulationQ36402640
Lysosomal glycosphingolipid recognition by NKT cellsQ40493118
Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim.Q40717909
The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cellsQ41815553
Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytesQ42635754
A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cellsQ43756252
Recognition of bacterial glycosphingolipids by natural killer T cellsQ44582192
Mechanism of CD1d-restricted natural killer T cell activation during microbial infection.Q47423311
Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptorsQ47662402
NKT cells: what's in a name?Q47895830
Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infectionsQ50092191
Control of NKT cell differentiation by tissue-specific microenvironmentsQ52004099
Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunityQ52005428
Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.Q52023804
Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesisQ52176215
Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation.Q53905529
Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.Q53963043
CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulationQ56905811
Protective effect of CTLA4Ig secreted by transgenic fetal pancreas allograftsQ56906014
Selective induction of NK cell proliferation and cytotoxicity by activated NKT cellsQ59387569
The Elusive NKT Cell Antigen--Is the Search Over?Q60489521
Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha -galactosylceramideQ60489559
Glycolipid Antigen Drives Rapid Expansion and Sustained Cytokine Production by NK T CellsQ62230390
NKT cells are phenotypically and functionally diverseQ62230500
Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramideQ63363334
The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic miceQ63363340
The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytesQ63363354
Mice deficient for the CD40 ligandQ72610555
Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cellsQ73098737
A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagementQ73201950
Requirement for IFN-gamma in IL-12 production induced by collaboration between v(alpha)14(+) NKT cells and antigen-presenting cellsQ73250789
Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathwaysQ73850509
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumorsQ78632792
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)3092-3101
P577publication date2005-09-01
P1433published inJournal of ImmunologyQ3521441
P1476titleNKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge
P478volume175

Reverse relations

cites work (P2860)
Q27300754A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect
Q35015787A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection
Q33988381Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS.
Q27318814Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis
Q53063140An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes
Q36239694Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans
Q37499317Antigen Presentation by CD1 Lipids, T Cells, and NKT Cells in Microbial Immunity
Q37288170Beta-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus
Q36474450Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants
Q37402372CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice
Q92092433CD160 serves as a negative regulator of NKT cells in acute hepatic injury
Q90259266CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
Q35524113CD1d-dependent expansion of NKT follicular helper cells in vivo and in vitro is a product of cellular proliferation and differentiation
Q36951719CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
Q38666579Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy
Q37083610Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells
Q81635265Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells
Q30374900Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.
Q36837547Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population
Q86497818Effective stimulation of invariant natural killer T cells by oligomannose-coated liposomes
Q38338690Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice
Q34781602Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant
Q38885794Glycolipid activators of invariant NKT cells as vaccine adjuvants
Q37187603Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants
Q48343602Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective
Q37388427Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges
Q37349692Harnessing invariant NKT cells in vaccination strategies
Q24650966How do natural killer T cells help B cells?
Q47350839IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
Q61823357ICOS-dependent stimulation of NKT cells by marginal zone B cells
Q33715268ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival
Q42141575IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset
Q41865525Id2 regulates hyporesponsive invariant natural killer T cells.
Q60311662Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses
Q51793903Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family.
Q38890717Immunotherapeutic strategies targeting natural killer T cell responses in cancer.
Q36597496Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice
Q51875279In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.
Q37286356Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin
Q35959395Influence of In Vitro IL-2 or IL-15 Alone or in Combination with Hsp 70 Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors on Peripheral Blood T Cells, B Cells and NKT Cells
Q36598607Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
Q83721502Introduction of aromatic group on 4′-OH of α-GalCer manipulated NKT cell cytokine production
Q37822744Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens
Q21284987Invariant NKT cells as novel targets for immunotherapy in solid tumors
Q30479030Invariant NKT cells sustain specific B cell responses and memory
Q37773278Invariant natural killer T cell-based immunotherapy for cancer
Q37322505Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner
Q36739848Invariant natural killer T cells: bridging innate and adaptive immunity
Q34120251KLRG+ invariant natural killer T cells are long-lived effectors
Q33724575Lipid and glycolipid antigens of CD1d-restricted natural killer T cells
Q37612720Mechanistic target of rapamycin complex 1 is critical for invariant natural killer T-cell development and effector function
Q61838047Miscarriage induced by adoptive transfer of dendritic cells and invariant natural killer T cells into mice
Q47094171Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy.
Q33739557NKG2A inhibits invariant NKT cell activation in hepatic injury
Q36739843NKT cell costimulation: experimental progress and therapeutic promise
Q40004498Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy
Q38148759Natural killer T cell based Immunotherapy
Q34043615Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies
Q36765720Natural killer T cells in health and disease
Q51828144Natural killer T cells: drivers or passengers in preventing human disease?
Q34748695Nonconventional CD8+ T cell responses to Listeria infection in mice lacking MHC class Ia and H2-M3
Q38206819Optimizing NKT cell ligands as vaccine adjuvants
Q30488777PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells
Q33753894PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
Q91971665Porcine Invariant Natural Killer T Cells: Functional Profiling and Dynamics in Steady State and Viral Infections
Q64076705Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy
Q39753175Rapid and reliable generation of invariant natural killer T-cell lines in vitro
Q53460588Reconstitution models to evaluate natural killer T cell function in tumor control
Q40659279Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell
Q54998990Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice.
Q92348502Roles of Natural Killer T Cells and Natural Killer Cells in Kidney Injury
Q40556221Selective Conditions Are Required for the Induction of Invariant NKT Cell Hyporesponsiveness by Antigenic Stimulation
Q33599059Stimulation of natural killer T cells by glycolipids
Q31153121Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge.
Q36439026Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice
Q38862782Synthesis and biological activities of C-glycosides of KRN 7000 with novel ceramide residues
Q26748456Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
Q37051132TCR-Dependent and -Independent Activation Underlie Liver-Specific Regulation of NKT Cells
Q36177350TLR4, 5, and 9 Agonists Inhibit Murine Airway Invariant Natural Killer T Cells in an IL-12-Dependent Manner
Q35516545Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
Q50531631The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens
Q35600087The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their Products
Q27023425The regulatory role of invariant NKT cells in tumor immunity
Q24648939The role of NKT cells in tumor immunity
Q36487076The role of invariant natural killer T cells in lupus and atherogenesis
Q55280646Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity.
Q37429039Transcriptional regulator Id2 controls survival of hepatic NKT cells
Q37662133Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity
Q37728011Type I natural killer T cells: naturally born for fighting
Q38562587mTOR and its tight regulation for iNKT cell development and effector function
Q37285232β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy

Search more.